Close Menu

On the Decline

The Wall Street Journal's Health Blog has put together a chart of R&D spending by US drug companies — a related article in the paper said that R&D fell in 2009 by 3.8 percent to $382.6 billion. Pfizer and Johnson and Johnson's spending dropped by 10.8 and 12.7 percent, respectively while the other companies showed gains in spending.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.